[go: up one dir, main page]

MA29463B1 - Compositions pharmaceutiques comprenant l'imatinibe et un retardateur de liberation - Google Patents

Compositions pharmaceutiques comprenant l'imatinibe et un retardateur de liberation

Info

Publication number
MA29463B1
MA29463B1 MA30391A MA30391A MA29463B1 MA 29463 B1 MA29463 B1 MA 29463B1 MA 30391 A MA30391 A MA 30391A MA 30391 A MA30391 A MA 30391A MA 29463 B1 MA29463 B1 MA 29463B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
imatinibe
release
delayer
contain
Prior art date
Application number
MA30391A
Other languages
English (en)
Inventor
Madhav Vasanthavada
Jay Parthiban Lakshman
Wei-Qin Tong
Abu T M Serajuddin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37027884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29463(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29463B1 publication Critical patent/MA29463B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/02—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor of articles of definite length, i.e. discrete articles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04—Particle-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/05—Filamentary, e.g. strands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/06—Rod-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/36—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die
    • B29C48/395—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders
    • B29C48/40—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders using two or more parallel screws or at least two parallel non-intermeshing screws, e.g. twin screw extruders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/88—Thermal treatment of the stream of extruded material, e.g. cooling
    • B29C48/911—Cooling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2001/00—Use of cellulose, modified cellulose or cellulose derivatives, e.g. viscose, as moulding material
    • B29K2001/08—Cellulose derivatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/25—Solid
    • B29K2105/251—Particles, powder or granules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037—Other properties
    • B29K2995/0056—Biocompatible, e.g. biopolymers or bioelastomers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037—Other properties
    • B29K2995/0059—Degradable
    • B29K2995/006—Bio-degradable, e.g. bioabsorbable, bioresorbable or bioerodible

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mechanical Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES À LIBÉRATION PROLONGÉE QUI CONTIENNENT DE L'IMATINIBE OU UN SEL DE L'IMATINIBE PHARMACEUTIQUEMENT ACCEPTABLE. LESDITES COMPOSITIONS PHARMACEUTIQUES RENFERMENT EN OUTRE UN RETARDATEUR DE LIBÉRATION, PAR EXEMPLE UN POLYMÈRE SOLUBLE DANS L'EAU, HYDROGONFLABLE ET/OU INSOLUBLE DANS L'EAU. L'INVENTION CONCERNE ENFIN UN PROCÉDÉ PARTICULIÈREMENT UTILE DE FABRICATION DE TELLES COMPOSITIONS PHARMACEUTIQUES À LIBÉRATION PROLONGÉE QUI UTILISE UNE EXTRUDEUSE.
MA30391A 2005-05-10 2007-11-20 Compositions pharmaceutiques comprenant l'imatinibe et un retardateur de liberation MA29463B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67960705P 2005-05-10 2005-05-10

Publications (1)

Publication Number Publication Date
MA29463B1 true MA29463B1 (fr) 2008-05-02

Family

ID=37027884

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30391A MA29463B1 (fr) 2005-05-10 2007-11-20 Compositions pharmaceutiques comprenant l'imatinibe et un retardateur de liberation

Country Status (32)

Country Link
US (2) US20080226731A1 (fr)
EP (1) EP1888040B1 (fr)
JP (1) JP5054000B2 (fr)
KR (2) KR101156916B1 (fr)
CN (1) CN101175483B (fr)
AR (1) AR054114A1 (fr)
AT (1) ATE477794T1 (fr)
AU (1) AU2006244359B2 (fr)
BR (1) BRPI0608605A2 (fr)
CA (1) CA2606602C (fr)
CY (1) CY1111389T1 (fr)
DE (1) DE602006016270D1 (fr)
DK (1) DK1888040T3 (fr)
ES (1) ES2350002T3 (fr)
GT (1) GT200600194A (fr)
HR (1) HRP20100615T1 (fr)
IL (1) IL186925A (fr)
JO (1) JO2647B1 (fr)
MA (1) MA29463B1 (fr)
MX (1) MX2007014067A (fr)
MY (1) MY148074A (fr)
NO (1) NO20076288L (fr)
NZ (1) NZ562538A (fr)
PE (1) PE20061449A1 (fr)
PL (1) PL1888040T3 (fr)
PT (1) PT1888040E (fr)
RU (1) RU2404775C2 (fr)
SA (1) SA06270134B1 (fr)
TN (1) TNSN07417A1 (fr)
TW (1) TWI368523B (fr)
WO (1) WO2006121941A2 (fr)
ZA (1) ZA200708839B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523083C (fr) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Analogues de phosphonate antiviraux
JP2008508291A (ja) 2004-07-27 2008-03-21 ギリアード サイエンシーズ， インコーポレイテッド 抗ｈｉｖ剤としてのヌクレオシドホスホネート結合体
ES2334933T3 (es) * 2005-08-15 2010-03-17 Siegfried Generics International Ag Comprimido recubierto o granulado que contiene una piridilpirimidina.
EP2068938B1 (fr) 2006-09-22 2011-01-19 Novartis AG Optimisation de traitement de la leucémie philadelphie positive avec l'inhibiteur de tyrosine kinase abl imatinib
EP1920767A1 (fr) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Forme posologique d'Imatinib préparée à l'état fondu.
CN101677955A (zh) * 2007-03-12 2010-03-24 雷迪博士实验室有限公司 甲磺酸伊马替尼
DK2305263T3 (da) * 2007-06-07 2012-10-22 Novartis Ag Stabiliserede amorfe former af imatinibmesylat
AU2012201613B2 (en) * 2007-06-07 2014-12-04 Novartis Ag Stabilized amorphous forms of Imatinib mesylate
WO2009028598A1 (fr) * 2007-08-31 2009-03-05 Daiichi Sankyo Company, Limited Préparation à libération prolongée et procédé de fabrication de celle-ci
US20090087489A1 (en) 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
EP2237783B1 (fr) 2008-01-23 2014-11-19 Novartis AG Procédé d'optimisation du traitement de maladies prolifératives à médiation par récepteur à tyrosine kinase kit avec de l'imatinib
WO2009100176A2 (fr) * 2008-02-07 2009-08-13 Abbott Laboratories Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase
CA2715422A1 (fr) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions pour la delivrance d'imatinib specifique du site et procedes d'utilisation
EP2307435B1 (fr) 2008-07-08 2012-06-13 Gilead Sciences, Inc. Sels de composés inhibiteurs du vih
WO2010065433A1 (fr) 2008-12-01 2010-06-10 Novartis Ag Méthode d’optimisation du traitement de la leucémie philadelphie positive avec du mésylate d’imatinib
WO2011121593A1 (fr) * 2010-03-29 2011-10-06 Hetero Research Foundation Composition pharmaceutique stable d'imatinib
WO2011161689A1 (fr) * 2010-06-21 2011-12-29 Suven Nishtaa Pharma Pvt Ltd Comprimé pharmaceutique de mésylate d'imatinib
MX2013001653A (es) 2010-08-11 2013-05-22 Synthon Bv Granulado farmaceutico que comprende mesilato de imatinib
WO2012080703A1 (fr) 2010-12-15 2012-06-21 Cipla Limited Composition pharmaceutique comprenant de l'imatinib
TR201010618A2 (tr) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
PL394169A1 (pl) * 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
US9750700B2 (en) * 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
WO2013008253A2 (fr) * 2011-07-11 2013-01-17 Dr. Reddys Laboratories Limited Formulations d'imatinib
JP6086520B2 (ja) * 2011-08-22 2017-03-01 大原薬品工業株式会社 薬物高含有固形製剤
BR112014012400A2 (pt) 2011-11-24 2017-06-13 Imuneks Farma Ilaç Sanayi Ve Ticaret A S formas de dosagens sólidas de imatinibe reconstituídas logo antes do uso
KR101428149B1 (ko) * 2011-12-23 2014-08-08 씨제이헬스케어 주식회사 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
JP6185559B2 (ja) * 2012-04-11 2017-08-23 ダウ グローバル テクノロジーズ エルエルシー 有機希釈剤およびセルロースエーテルを含む組成物
EP2836235B1 (fr) * 2012-04-11 2017-03-08 Dow Global Technologies LLC Nouvelles formes pharmaceutiques à libération prolongée
US9364546B2 (en) 2012-04-11 2016-06-14 Dow Global Technologies Llc Melt-extruded composition comprising a cellulose ether
RU2517216C2 (ru) * 2012-08-22 2014-05-27 Закрытое Акционерное Общество "БИОКАД" (ЗАО "БИОКАД") Фармацевтическая композиция иматиниба или его фармацевтически приемлемой соли, способ ее получения и способ(ы) лечения
ES2778040T3 (es) * 2013-05-27 2020-08-07 Steerlife India Private Ltd Un extrusor y proceso de fragmentación por fusión en caliente
EP3019159A4 (fr) * 2013-07-09 2017-01-18 Shilpa Medicare Limited Compositions pharmaceutiques orales comprenant du mésylate d'imatinib
WO2015165975A1 (fr) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pour traiter des néoplasies myéloïdes
CN104146973B (zh) * 2014-08-14 2017-09-05 杭州华东医药集团新药研究院有限公司 一种含有甲磺酸伊马替尼组合物及其制备方法
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
SE539450C2 (en) * 2016-02-29 2017-09-26 Imatinib for use in the treatment of stroke
EP3661937B1 (fr) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Formes crystallines d'éthyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)méthyl)(phénoxy)phosphoryl)-l-alaninate (gs-9131) pour le traitement des infections virales
EA033102B1 (ru) * 2017-08-21 2019-08-30 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция с модифицированным отсроченным и длительным высвобождением, содержащая аспарагинаты
US20220265653A1 (en) * 2019-07-15 2022-08-25 Intas Pharmaceuticals Ltd. Pharmaceutical composition of imatinib
US20220175812A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
DE10026699A1 (de) * 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
JP4121372B2 (ja) * 2001-02-27 2008-07-23 千寿製薬株式会社 生分解性ポリマー型薬物放出システム
DE10207586A1 (de) 2002-02-22 2003-09-11 Degussa Herstellung von N-Methyl-3-hydroxy-3-(2-thienyl)propanamin über neue carbamatgruppenhaltige Thiophenderivate als Zwischenprodukte
JP2005527523A (ja) * 2002-03-15 2005-09-15 ノバルティス　アクチエンゲゼルシャフト ＡｎｇＩＩ介在性疾病を処置するための４−（４−メチルピペラジン−１−イルメチル）−Ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イル−アミノ］フェニル］−ベンズアミド
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1509219A1 (fr) * 2002-05-13 2005-03-02 Beth Israel Deaconess Medical Center Methodes et compositions de traitement du rejet de greffe
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
WO2006040779A2 (fr) * 2004-10-11 2006-04-20 Natco Pharma Limited Formule à matrice flottante gastrique à libération contrôlée contenant la substance imatinib
WO2006048890A1 (fr) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Forme cristalline d'imatinib mesylate et procede d'elaboration

Also Published As

Publication number Publication date
TW200716205A (en) 2007-05-01
IL186925A (en) 2011-11-30
PL1888040T3 (pl) 2011-02-28
WO2006121941A3 (fr) 2007-01-11
TWI368523B (en) 2012-07-21
NZ562538A (en) 2011-03-31
ATE477794T1 (de) 2010-09-15
DK1888040T3 (da) 2010-11-15
AU2006244359B2 (en) 2010-12-09
GT200600194A (es) 2006-12-04
ES2350002T3 (es) 2011-01-14
WO2006121941A2 (fr) 2006-11-16
BRPI0608605A2 (pt) 2010-01-19
CN101175483B (zh) 2012-06-20
RU2404775C2 (ru) 2010-11-27
KR20080007249A (ko) 2008-01-17
AR054114A1 (es) 2007-06-06
TNSN07417A1 (en) 2009-03-17
EP1888040B1 (fr) 2010-08-18
CA2606602C (fr) 2013-08-27
MX2007014067A (es) 2008-02-07
KR101156916B1 (ko) 2012-06-21
NO20076288L (no) 2008-02-05
DE602006016270D1 (de) 2010-09-30
KR20100044286A (ko) 2010-04-29
RU2007145507A (ru) 2009-06-20
HK1116067A1 (en) 2008-12-19
MY148074A (en) 2013-02-28
US20080226731A1 (en) 2008-09-18
JP5054000B2 (ja) 2012-10-24
SA06270134B1 (ar) 2009-02-07
CY1111389T1 (el) 2015-08-05
CA2606602A1 (fr) 2006-11-16
US20140350027A1 (en) 2014-11-27
IL186925A0 (en) 2008-02-09
EP1888040A2 (fr) 2008-02-20
ZA200708839B (en) 2008-11-26
JO2647B1 (en) 2012-06-17
PE20061449A1 (es) 2007-01-20
PT1888040E (pt) 2010-10-28
CN101175483A (zh) 2008-05-07
AU2006244359A1 (en) 2006-11-16
HRP20100615T1 (hr) 2010-12-31
JP2008540531A (ja) 2008-11-20

Similar Documents

Publication Publication Date Title
MA29463B1 (fr) Compositions pharmaceutiques comprenant l'imatinibe et un retardateur de liberation
WO2006000228A3 (fr) Preparation de compositions pharmaceutiques de medicaments insolubles a l'eau a diffusion rapide et compositions pharmaceutiques ainsi preparees
MA31797B1 (fr) Compositions pharmaceutiques
WO2001076561A3 (fr) Compositions pharmaceutiques
WO2006013369A3 (fr) Compositions formant des dispersions non lamellaires
WO2006105112A3 (fr) Compositions contenant des acides amines pour la prevention ou le traitement dans le muscle squelettique de personnes agees
EP2638905A3 (fr) Traitement de biofilm
WO2006012527A8 (fr) Groupes de liaison bivalents et conjugués de ceux-ci
WO2006091529A3 (fr) Preparation pharmaceutique solide
WO2002078648A3 (fr) Composition topique
WO2005007115A3 (fr) Formulations pharmaceutiques utilisees pour inhiber une secretion acide et procede de fabrication associe
WO2007106436A3 (fr) Composes et compositions photoactifs et utilisations derivees
WO2004091497A3 (fr) Methodes et compositions pouvant augmenter la capacite de travail anaerobie dans des tissus
WO2008036864A3 (fr) Inhibition de la maturation d'ostwald dans des formulations chimiques
WO2006029155A3 (fr) Compositions ghb ameliorees
WO2006036614A3 (fr) Nouvelle classe de materiaux de type tensioactif
WO2003051300A8 (fr) Complexes metalliques et formulations d'analogues de rifamycine, utilisations correspondantes
WO2007075972A3 (fr) Formulations de chlorite et leurs procédés de préparation et d'utilisation
WO2007016352A3 (fr) Compositions orales liquides de losartan
JP2004505922A5 (fr)
WO2007048027A3 (fr) Combinaison de composes organiques
WO2005121778A3 (fr) Procedes d'identification, et composes utiles pour le traitement de maladies degeneratives et inflammatoires
MX2008002493A (es) Composicion farmaceutica solida que comprende 1-(4-cloro-anilino)-4-(4-piridil-metil)-ftalazina y un modificador del ph.
MA29492B1 (fr) Formulations stables de nanoparticules
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина